Trial Profile
Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms BIOMARK
- Sponsors EPS Corporation
- 07 Dec 2022 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 According to UMIN, the date for data entry closure is 2019/02/25, and the date for conclusion of data analysis is 2019/03/31.
- 19 Feb 2019 Planned End Date changed from 31 Mar 2019 to 31 Jan 2019.